Healius has shocked investors by lowering its full-year earnings forecast by 20 per cent, blaming a decline in demand for its pathology unit, while also revealing it intended to sell its clinical ...
The news: Pathology provider Healius has appointed UBS to explore a sale of its bioanalytical laboratory Agilex Biolabs in response to “several unsolicited approaches from credible parties”. The ...
In 2018, the former Primary Healthcare rebranded itself as Healius to signify the strategic turnaround underway. Healius is looking to new sources of strategic growth as well as dealing with prior ...
In May 2026, Healius Limited (ASX:HLS) said it had engaged UBS Securities Australia to explore a potential sale of its standalone Agilex Biolabs business after receiving unsolicited approaches, while ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results